Michael Barbella, Managing Editor04.06.24
MPO website visitors apparently were looking for approval this past week.
Product authorization, acquisition and patent resolution news drove the bulk of online traffic in the first week of April.
Abbott was the top pageview producer, having gained FDA approval for its TriClip transcatheter edge-to-edge repair (TEER) system for treating tricuspid regurgitation (TR), or a leaky tricuspid valve. Delivered through a leg vein, the TriClip TEER works by clipping together part of the leaflets to repair the tricuspid valve to help blood flow in the right direction without needing open-heart surgery. On average, TriClip patients need one day in the hospital before recovery.
Olympus attracted cybervisitor interest as well by receiving FDA 510(k) clearance for its first single-use ureteroscope system, RenaFlex. The product is used to access and visualize the urinary tract to diagnose and treat urinary diseases and disorders like kidney stones. It visualizes organs, cavities, and canals in the urinary tract via transurethral or percutaneous access routes.
Not surprisingly, KARL STORZ SE & Co. KG's buyout bid for Asensus Surgical generated significant reader interest, as did the resolution of AngioDynamics' multi-year patent dispute with BD (Becton, Dickinson and Company) affiliate C.R. Bard (legal trouble and acquisitions typically are fan favorites).
Product authorization, acquisition and patent resolution news drove the bulk of online traffic in the first week of April.
Abbott was the top pageview producer, having gained FDA approval for its TriClip transcatheter edge-to-edge repair (TEER) system for treating tricuspid regurgitation (TR), or a leaky tricuspid valve. Delivered through a leg vein, the TriClip TEER works by clipping together part of the leaflets to repair the tricuspid valve to help blood flow in the right direction without needing open-heart surgery. On average, TriClip patients need one day in the hospital before recovery.
Olympus attracted cybervisitor interest as well by receiving FDA 510(k) clearance for its first single-use ureteroscope system, RenaFlex. The product is used to access and visualize the urinary tract to diagnose and treat urinary diseases and disorders like kidney stones. It visualizes organs, cavities, and canals in the urinary tract via transurethral or percutaneous access routes.
Not surprisingly, KARL STORZ SE & Co. KG's buyout bid for Asensus Surgical generated significant reader interest, as did the resolution of AngioDynamics' multi-year patent dispute with BD (Becton, Dickinson and Company) affiliate C.R. Bard (legal trouble and acquisitions typically are fan favorites).